QQQ $ 603.76 $ 6.12 (1.02 %)
DIA $ 461.93 $ 2.57 (0.56 %)
SPY $ 663.91 $ 4.45 (0.67 %)
TLT $ 91.16 $ -0.07 (-0.08 %)
GLD $ 389.93 $ -7.29 (-1.84 %)
$ 0.0111
-- x --
-- x --
-- - --
$ 0.01 - $ 26.25
2,064
na
1,889
$ 1.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-03-2025 01-01-1970 10-K
2 11-14-2024 09-30-2024 10-Q
3 08-12-2024 06-30-2024 10-Q
4 05-13-2024 03-31-2024 10-Q
5 03-26-2024 12-31-2023 10-K
6 12-07-2023 09-30-2023 10-Q
7 08-14-2023 06-30-2023 10-Q
8 05-12-2023 03-31-2023 10-Q
9 03-22-2023 12-31-2022 10-K
10 11-09-2022 09-30-2022 10-Q
11 08-15-2022 06-30-2022 10-Q
12 05-16-2022 03-31-2022 10-Q
13 03-31-2022 12-31-2021 10-K
14 11-15-2021 09-30-2021 10-Q
15 08-09-2021 06-30-2021 10-Q
16 05-17-2021 03-31-2021 10-Q
17 03-31-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 us-stocks-likely-to-open-lower-after-fed-decision-any-pullback-in-equities-offers-an-opportunity-says-expert

U.S. stock futures rose on Thursday following the Federal Open Market Committee's decision on Wednesday calling inflation &...

 virpax-reveals-results-from-a-beagle-dog-dose-range-finding-study-all-the-dogs-in-drf-study-demonstrated-positive-tolerance-to-probudur-and-no-adverse-effects-were-noted

Probudur is the company's long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate ...

 us-stocks-likely-to-open-higher-following-a-sell-off-this-choppy-start-to-2025-isnt-abnormal-dont-panic-says-expert-highlighting-seasonal-weakness-in-the-first-quarter-after-elections

U.S. stock futures rose on Friday following Thursday's sell-off. Futures advanced except the small-cap gauge Russell 2000.

 penny-stock-virpax-pharmaceuticals-surges-on-us-army-performed-preclinical-study-for-pain-candidate

Virpax completed a U.S. Army-backed Probudur study, showing potential for prolonged pain relief and reduced opioid use in surgi...

 virpax-confirms-results-with-us-army-with-probudur-for-combat-care-study-showing-incision-pain-reduction-in-rat-model-aiming-to-reduce-opioid-need-long-duration-pain-control-demonstrated-up-to-5-days

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing no...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION